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Aims Iron deficiency (ID) is associated with poor prognosis regardless of anaemia. Intravenous iron improves quality of
life and outcomes in patients with ID and heart failure (HF) with reduced ejection fraction (HFrEF). In the Swedish
HF registry, we assessed (i) frequency and predictors of ID testing; (ii) prevalence and outcomes of ID with/without
anaemia; (iii) use of ferric carboxymaltose (FCM) and its predictors in patients with ID.
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Methods
and results
We used multivariable logistic regressions to assess patient characteristics independently associated with ID
testing/FCM use, and Cox regressions to assess risk of outcomes associated with ID. Of 21 496 patients with HF
and any ejection fraction enrolled in 2017–2018, ID testing was performed in 27%. Of these, 49% had ID and more
specifically 36% had ID−/anaemia−, 15% ID−/anaemia+, 29% ID+/anaemia−, and 20% ID+/anaemia+ (48%, 39%,
13%, 30% and 18% in HFrEF, respectively). Risk of recurrent all-cause hospitalizations was higher in patients with
ID regardless of anaemia. Of 1959 patients with ID, 19% received FCM (24% in HFrEF). Important independent
predictors of ID testing and FCM use were anaemia, higher New York Heart Association class, having HFrEF, and
referral to HF specialty care.
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Conclusion In this nationwide HF registry, ID testing occurred in only about a quarter of the patients. Among tested patients, ID
was present in one half, but only one in five patients received FCM indicating low adherence to current guidelines on
screening and treatment.
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Graphical Abstract
Iron deficiency (ID) testing use, prevalence of ID/anaemia (A), and use of ferric carboxymaltose (FCM) in the unmatched cohort across the ejection
fraction spectrum. HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction;
HFrEF, heart failure with reduced ejection fraction.
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Introduction
Iron deficiency (ID) is highly prevalent in patients with chronic
heart failure (HF) and independently associated with high risk of
hospitalizations and mortality.1 ID is the main cause of anaemia and
is documented in almost 50% of HF patients in Europe.2 In addition,
it has been shown to impact prognosis per se, i.e. independently of
anaemia and chronic kidney disease, in patients with HF.1,3 Based
on these prognostic implications, the 2016 European Society of
Cardiology (ESC) guidelines on HF recommend testing for ID in
all newly diagnosed patients with HF regardless of haemoglobin
levels.4
Treatment with oral iron has not been successful in improving
outcomes in HF patients and might be limited by low absorption
and high occurrence of gastrointestinal side effects.5 Several ran-
domized controlled trials (RCTs) demonstrated intravenous (IV)
iron treatment with ferric carboxymaltose (FCM) improving symp-
toms, quality of life, functional capacity and reducing risk of HF
hospitalizations in patients with symptomatic HF with ejection
fraction (EF) <50% and ID regardless of concomitant anaemia.6–9
Therefore, based on the available data, the 2016 ESC guidelines on
HF had class IIa, level of evidence A recommendation for FCM in
patients with symptomatic HF with reduced EF (HFrEF) and ID in
order to improve quality of life, exercise capacity and lessen HF
symptoms.4
Despite proven efficacy for optimal guideline-directed medical
therapy from RCTs, patients with HFrEF are often undertreated or
receive suboptimal doses of HF medications.10 Additionally, limited














































. Thus, we aimed to (i) assess the likelihood of being tested
for ID and identify patient characteristics independently associ-
ated with it; (ii) phenotype patients with HF and ID; and (iii)
assess the use of FCM and the independent predictors of its
use in a real-world cohort of patients with HF across the EF
spectrum.
Methods
Study protocol and setting
The Swedish Heart Failure Registry (SwedeHF, www.swedeHF.se) has
been described previously.11 For the current analysis, SwedeHF was
linked with the National Patient Registry, Statistics Sweden and the
Cause of Death Registry. More details on the data sources are reported
in the online supplementary Methods S1.
Study population
Patient selection is illustrated in online supplementary Figure S1. For
the analyses focusing on ID testing, the study population consisted
of all patients enrolled in SwedeHF between 1 January 2017 and
31 December 2018 (as ID biomarkers were collected in SwedeHF
during this period but not earlier). For the analyses aiming to char-
acterize ID and to investigate FCM use, registrations with missing
data for ferritin/transferrin saturation levels, haemoglobin, and use of
FCM were excluded. If the same patient had multiple registrations in
SwedeHF, the first one reporting data on the biomarkers of interest
was selected. The index date was defined as either the day of the
outpatient visit or of hospital discharge linked with the registration in
SwedeHF.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Statistical analyses
Missing data
Of 28 919 registrations in SwedeHF between 1 January 2017 and
31 December 2018, 22 602 (78%) missing values were reported
for ferritin, 24 037 (83%) for transferrin saturation, 4979 (17%) for
haemoglobin, and 1190 (4%) for FCM use. Missing data for variables
considered for adjustments in the multivariable models were handled
by chained-equations multiple imputation (R package mice). Analyses
were performed in 10 imputed datasets and then the estimates
were combined by Rubin’s rules. Variables used for the multiple
imputation are marked in Table 1 and online supplementary Table S1.
The composite outcome of first HF hospitalization/all-cause death was
included as the Nelson–Aalen estimator.
Definitions
Patients were considered as tested for ID whether they had a ferritin
or transferrin saturation measurement, i.e. missing values were inter-
preted as lack of testing.
Overall, ID was defined as ferritin <100 μg/L, or ferritin between
100–299 μg/L and transferrin saturation <20%.4 However, in the
analyses aiming to explore the use of FCM, we assumed that patients
who were reported as treated with FCM but who did not fulfil
the criteria for a diagnosis of ID had normalized ferritin/transferrin
saturation levels following a previous treatment with FCM (n = 55).
Therefore, these patients were assumed as with ID. Anaemia was
defined as haemoglobin <12.0 g/dL in women and <13.0 g/dL in men.4
Patient characteristics
Baseline characteristics were compared across patients with vs.
without ID, also stratifying by anaemia status, i.e. ID−/anaemia−,
ID−/anaemia+, ID+/anaemia−, ID+/anaemia+, by Kruskal–Wallis (if
continuous) and by chi-squared test (if categorical). Similarly, patient
characteristics were compared in patients receiving vs. not receiving
ID testing and FCM (online supplementary Table S2).
To evaluate patient characteristics which were independently
associated with ID testing and use of FCM, logistic regression
models were fitted, with use of ID testing and use of FCM,
respectively, as dependent variables and the patient characteris-
tics reported in Figure 1 as covariates. Odds ratio (OR) and 95%
confidence interval (CI) were calculated for each potential predictor.
In patients receiving FCM, the used doses were visualized by a Kernel
density plot.
Outcome analysis
We assessed the associations between ID/anaemia and fer-
ritin/transferrin saturation levels with the following outcomes: a
composite of time to first HF hospitalization or all-cause death,
time to first HF hospitalization, time to all-cause death, time to first
all-cause hospitalization, time to first HF outpatient visit as well as
the total number of HF hospitalizations, all-cause hospitalizations
and HF outpatient visits. Data were censored on 31 December
2018 or at death (if not defined as an event)/emigration from
Sweden.
To investigate the association between ID/anaemia, fer-
ritin/transferrin saturation levels and outcomes, cumulative incidence
curves were fitted. Multivariable Cox regression models for time



















































































.. log of time as an offset in the model) for repeated event analyses
were performed to provide adjusted estimates (variables used for the
adjustment are marked in Table 1 and online supplementary Table S1).
The proportional hazard assumption was verified by Schoenfeld
residuals and met.
All statistical analyses were performed by R 4.0.2 and the R code
for data handling and statistical analyses can be found at https://github
.com/KIHeartFailure/iron. A two-sided P-value <0.05 was considered
as statistically significant.
Results
Iron deficiency testing and predictors
of iron deficiency testing use
Between 1 January 2017 and 31 December 2018, there were
21 496 patients registered in SwedeHF and 5708 (27%) were
tested for ID [i.e. measurement of only ferritin (1472, 7%), of
only transferrin saturation (221, 1%), or of both ferritin and
transferrin saturation (4015, 19%)] (Graphical Abstract, Table 1,
online supplementary Table S3). Of these, 2691 (57%) had HFrEF,
1113 (24%) HF with mildly reduced EF (HFmrEF), and 907 (19%)
HF with preserved EF (HFpEF). ID testing was performed in 32%
of patients with anaemia and 28% of those without anaemia, with
similar differences in testing according to anaemia status across the
EF spectrum (Graphical Abstract).
Of all tested variables, key patient characteristics independently
associated with higher likelihood of ID testing were enrolment in
SwedeHF registry as an outpatient, having HFrEF vs. HFmrEF vs.
HFpEF, more severe/symptomatic HF [i.e. higher New York Heart
Association (NYHA) class, use of diuretics and mineralocorticoid
receptor antagonists (MRAs)], use of beta-blockers, anaemia, male
sex, longer HF duration, follow-up referral to HF nurse-led clinic,
referral to follow-up in primary care, and being registered in
SwedeHF in 2018 vs. 2017 (Figure 1). Geographical distribution of
ID testing in Sweden is shown in online supplementary Figure S2
and Table S4.
Characterization of iron deficiency
Prevalence
Of 3757 patients with available data on ferritin, transferrin satu-
ration, haemoglobin and FCM, 36% had neither ID nor anaemia
(ID−/anaemia−), 29% had only ID (ID+/anaemia−), 15% had only
anaemia (ID−/anaemia+), and 20% had both ID and anaemia
(ID+/anaemia+) (Graphical Abstract, Table 2, online supplemen-
tary Table S5). In patients with HFpEF, 27% had ID−/anaemia−,
27% had ID+/anaemia−, 17% had ID−/anaemia+, and 29% had
ID+/anaemia+. Corresponding estimates in patients with HFmrEF
were 34% for ID−/anaemia−, 28% for ID+/anaemia−, 16% for
ID−/anaemia+, and 22% for ID+/anaemia+. In HFrEF, 39% had
ID−/anaemia−, 30% ID+/anaemia−, 13% ID−/anaemia+, and 18%
ID+/anaemia+ (Graphical Abstract, Table 2, online supplementary
Tables S6–S8). Prevalence of ID regardless of anaemia was 49% in
the overall population, 56% in HFpEF, 50% in HFmrEF, and 48% in
HFrEF.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics in patients with vs. without iron deficiency testing (i.e. measurement of ferritin or
transferrin saturation)
Variable Missing ID testing No ID testing Yes P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
n (%) 15 788 (73) 5708 (27)
Male sexa, n (%) 0.0 10 025 (63.5) 3810 (66.7) <0.001
Age (years)a, n (%) 0.0 75.0 [67.0–82.0] 75.0 [66.0–81.0] <0.001
Outpatient locationa, n (%) 0.0 11 497 (72.8) 5120 (89.7) <0.001
LVEF, n (%)a 14.4 <0.001
HFrEF 6713 (49.0) 2691 (57.1)
HFmrEF 3543 (25.9) 1113 (23.6)
HFpEF 3433 (25.1) 907 (19.3)
NYHA classa, n (%) 27.9 <0.001
I 1366 (12.7) 452 (9.5)
II 5462 (50.9) 2255 (47.4)
III 3707 (34.5) 1992 (41.8)
IV 202 (1.9) 61 (1.3)
Systolic blood pressure (mmHg), median [IQR] 3.4 130.0 [115.0–140.0] 125.0 [110.0–140.0] <0.001
Diastolic blood pressure (mmHg), median [IQR] 3.2 75.0 [67.0–80.0] 70.0 [65.0–80.0] <0.001
Heart rate (bpm), median [IQR] 4.6 72.0 [64.0–84.0] 70.0 [62.0–80.0] <0.001
BMI (kg/m2), median [IQR] 44.2 27.0 [23.8–30.9] 26.6 [23.7–30.5] 0.019
eGFR (CKD-EPI) (mL/min/1.73 m2), median [IQR] 4.8 61.8 [45.6–79.6] 62.1 [45.1–79.8] 0.865
NT-proBNP (pg/mL), median [IQR] 25.5 1975.0 [781.0–4338.0] 1864.0 [766.5–4000.0] 0.038
Smoking, former/currenta, n (%) 33.4 5547 (54.7) 2434 (58.1) <0.001
Diabetesa, n (%) 0.0 4340 (27.5) 1561 (27.3) 0.851
Atrial fibrillation/fluttera, n (%) 0.0 9144 (57.9) 3193 (55.9) 0.010
Ischaemic heart diseasea, n (%) 0.0 7992 (50.6) 2940 (51.5) 0.258
Hypertensiona, n (%) 0.0 11 170 (70.7) 3968 (69.5) 0.083
Valvular heart diseasea, n (%) 0.0 3017 (19.1) 1022 (17.9) 0.048
COPDa, n (%) 0.0 2102 (13.3) 730 (12.8) 0.326
ACEi/ARB/ARNia, n (%) 0.6 13 306 (85.0) 5051 (88.7) <0.001
Beta-blockera, n (%) 0.3 13 986 (88.9) 5201 (91.2) <0.001
MRAa, n (%) 0.5 6385 (40.7) 2657 (46.6) <0.001
Device therapy (CRT/ICD)a, n (%) 1.6 1837 (11.9) 764 (13.5) 0.002
Diuretica, n (%) 0.5 11 367 (72.5) 4298 (75.5) <0.001
Statina, n (%) 0.4 7873 (50.1) 2995 (52.5) 0.002
Nitratea, n (%) 0.5 1545 (9.8) 534 (9.4) 0.327
Follow-up referral HF nurse-led clinica, n (%) 6.7 11 219 (77.2) 4810 (87.3) <0.001
Follow-up referral specialtya, n (%) 3.9 <0.001
Hospital 10 099 (67.1) 3933 (70.2)
Primary care 4707 (31.3) 1618 (28.9)
Other 251 (1.7) 54 (1.0)
Educationa, n (%) 1.6 0.022
Compulsory school 6041 (38.9) 2071 (36.9)
Secondary school 6534 (42.1) 2464 (43.9)
University 2954 (19.0) 1081 (19.2)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; CKD-EPI, Chronic
Kidney Disease Epidemiology Collaboration; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration
rate; HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced
ejection fraction; ICD, implantable cardioverter-defibrillator; ID, iron deficiency; IQR, interquartile range; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid
receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
aIncluded in the multiple imputation models and logistic/Cox regressions.
Baseline characteristics according to iron deficiency
and anaemia status
Regardless of the EF phenotype, patients with ID−/anaemia+ and
ID+/anaemia+ were more likely older, more symptomatic for HF
[i.e. higher NYHA class and N-terminal pro-B-type natriuretic








.. to have ischaemic heart disease (Table 2, online supplementary
Table S5).
Patients with ID+/anaemia+ were more likely to have HFpEF,
more symptomatic/severe HF (i.e. higher NYHA class, higher
NT-proBNP, use of diuretics and nitrates) and higher comorbid-
ity burden (ischaemic heart disease, diabetes, hypertension, prior
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Predictors of iron deficiency (ID) testing use (A) and predictors of ferric carboxymaltose (FCM) use (B). ACEi, angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; COPD, chronic
obstructive pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; HB, haemoglobin; HF,
heart failure; ICD, implantable cardioverter-defibrillator; MAP, mean arterial pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide;
NYHA, New York Heart Association; MRA, mineralocorticoid receptor antagonist.
stroke, chronic obstructive pulmonary disease, valvular disease)
and to be followed up in primary care compared with those with
ID−/anaemia− (Table 2, online supplementary Tables S5 and S6).
Patients with ID−/anaemia+ showed a profile which resembled
more ID+/anaemia+, whereas ID+/anaemia− resembled more
ID−/anaemia−. Use of HF treatments (i.e. MRA and device ther-
apy) was highest in patients with ID+/anaemia− and ID−/anaemia−,
who also were more likely to have preserved renal function and
HFrEF (online supplementary Table S8). Overall, patient charac-
teristics according to ID/anaemia were consistent across the EF
spectrum (online supplementary Tables S6–S8).
Outcome analysis according to iron deficiency
and anaemia status
Over a median (interquartile range) follow-up of 19.4 (0.1–35.9)
months, in time to event analyses and compared with
ID−/anaemia−, ID+/anaemia+ was associated with the higher
risk of all the outcomes [all-cause death/first HF hospitalization:
adjusted hazard ratio (HR) 1.48 (95% CI 1.25–1.74), P < 0.001;
all-cause death: adjusted HR 1.55 (95% CI 1.23–1.95), P < 0.001;
first HF hospitalization: adjusted HR 1.38 (95% CI 1.14–1.67),
P = 0.001; and first all-cause hospitalization: adjusted HR 1.39
(95% CI 1.23–1.58), P < 0.001] except for first HF visit (whose
risk was similar across the study groups); ID−/anaemia+ was asso-
ciated with higher risk of all-cause death/first HF hospitalization







































.. death [adjusted HR 1.41 (95% CI 1.10–1.82), P = 0.008]; there
were no statistically significant differences in risk of outcomes
with ID+/anaemia− (Figure 2, Table 3, online supplementary
Figure S3).
In the recurrent event analyses, ID+/anaemia+ was associ-
ated with statistically significant higher risk of all-cause and HF
hospitalizations [adjusted incident rate ratio [IRR] 1.43 (95% CI
1.25–1.63), P < 0.001; and adjusted IRR 1.37 (95% CI 1.10–1.72),
P = 0.005], whereas ID+/anaemia− [adjusted IRR 1.17 (95% CI
1.04–1.31), P = 0.008] and ID−/anaemia+ [adjusted IRR 1.30 (95%
CI 1.12–1.50), P < 0.001] with higher risk of all-cause hospitaliza-
tions compared with ID−/anaemia− (Table 3).
Of note, when included in the same Cox regression (includ-
ing also the covariates reported in Table 1), transferrin saturation
<20% vs. ≥20% was significantly associated with higher risk of all
the investigated outcomes (i.e. all-cause death/first HF hospitaliza-
tion, all-cause death, first and recurrent HF hospitalizations, first
and recurrent all-cause hospitalizations, first and recurrent HF vis-
its), whereas ferritin <100 vs. ≥100 μg/L was only associated with
higher risk of recurrent HF hospitalizations and recurrent all-cause
hospitalizations (online supplementary Table S9).
Characterizing ferric carboxymaltose use
Ferric carboxymaltose use
In the overall HF cohort with ID, 19% of patients received FCM
treatment and of these 52% had anaemia (Graphical Abstract, online
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Baseline characteristics in the study population stratified according to iron deficiency/anaemia status
Variable Missing ID−/A− ID−/A+ ID+/A− ID+/A+ P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
n (%) 1351 (36) 541 (15) 1100 (29) 765 (20)
Male sexa, n (%) 0.0 985 (72.9) 444 (82.1) 654 (59.5) 496 (64.8) <0.001
Age (years), median [IQR] 0.0 72.0 [64.0–78.5] 77.0 [71.0–83.0] 73.0 [63.0–79.2] 77.0 [71.0–84.0] <0.001
Outpatient locationa, n (%) 0.0 1299 (96.2) 471 (87.1) 1047 (95.2) 611 (79.9) <0.001
HF subtypea, n (%) 15.0 <0.001
HFrEF 749 (65.0) 249 (54.0) 571 (61.8) 334 (50.8)
HFmrEF 249 (21.6) 117 (25.4) 202 (21.9) 159 (24.2)
HFpEF 155 (13.4) 95 (20.6) 151 (16.3) 164 (25.0)
NYHA classa, n (%) 16.2 <0.001
I 153 (13.1) 36 (8.4) 86 (9.1) 31 (5.2)
II 599 (51.2) 191 (44.3) 468 (49.3) 225 (37.8)
III 406 (34.7) 200 (46.4) 390 (41.1) 327 (54.9)
IV 12 (1.0) 4 (0.9) 6 (0.6) 13 (2.2)
Systolic blood pressure (mmHg),
median [IQR]
2.0 125.0 [110.0–140.0] 121.0 [110.0–135.0] 125.0 [111.0–140.0] 126.0 [110.0–140.0] 0.005
Diastolic blood pressure (mmHg),
median [IQR]
1.8 73.0 [65.0–80.0] 70.0 [60.0–79.5] 73.0 [65.0–80.0] 70.0 [60.0–80.0] <0.001
Heart rate (bpm), median [IQR] 2.4 69.0 [60.0–79.0] 70.0 [61.0–80.0] 70.0 [62.0–80.0] 72.0 [64.0–82.0] <0.001




0.5 68.0 [52.1–82.6] 52.7 [37.9–72.3] 65.5 [48.8–83.2] 52.6 [39.0–70.1] <0.001
NT-proBNP (pg/mL), median
[IQR]
10.0 1293.5 [527.2–2668.0] 2890.0 [1332.0–6008.0] 1590.0 [596.0–3471.0] 3196.5 [1420.0–6921.2] <0.001
Smoking, former/currenta, n (%) 27.1 574 (58.0) 213 (56.6) 489 (60.1) 341 (61.2) 0.423
Diabetesa, n (%) 0.0 294 (21.8) 159 (29.4) 307 (27.9) 267 (34.9) <0.001
Atrial fibrillation/fluttera, n (%) 0.0 744 (55.1) 322 (59.5) 560 (50.9) 457 (59.7) <0.001
Ischaemic heart diseasea, n (%) 0.0 632 (46.8) 328 (60.6) 572 (52.0) 469 (61.3) <0.001
Hypertensiona, n (%) 0.0 855 (63.3) 391 (72.3) 739 (67.2) 607 (79.3) <0.001
Valvular heart diseasea, n (%) 0.0 211 (15.6) 130 (24.0) 176 (16.0) 204 (26.7) <0.001
COPDa, n (%) 0.0 126 (9.3) 71 (13.1) 151 (13.7) 131 (17.1) <0.001
RASi/ARNia, n (%) 0.2 1268 (94.0) 474 (87.6) 995 (90.8) 638 (83.5) <0.001
Beta-blockera, n (%) 0.1 1261 (93.3) 487 (90.0) 1030 (93.9) 678 (88.6) <0.001
MRAa, n (%) 0.1 743 (55.0) 242 (44.7) 517 (47.1) 358 (46.8) <0.001
Device therapy (CRT/ICD)a, n (%) 0.4 249 (18.5) 79 (14.7) 180 (16.5) 65 (8.6) <0.001
Diuretica, n (%) 0.2 946 (70.0) 444 (82.1) 787 (71.8) 639 (83.7) <0.001
Statina, n (%) 0.1 691 (51.2) 303 (56.0) 583 (53.1) 449 (58.8) 0.006
Nitrate, n (%)a 0.2 63 (4.7) 69 (12.8) 112 (10.2) 102 (13.4) <0.001
Follow-up referral HF nurse-led
clinica, n (%)




Hospital 1106 (82.7) 406 (76.3) 865 (79.4) 539 (72.3)
Primary care 225 (16.8) 117 (22.0) 215 (19.7) 192 (25.8)
Other 7 (0.5) 9 (1.7) 10 (0.9) 14 (1.9)
Educationa, n (%) 1.7 0.006
Compulsory school 415 (31.3) 213 (39.7) 377 (34.9) 290 (38.5)
Secondary school 619 (46.7) 223 (41.6) 493 (45.6) 320 (42.5)
University 292 (22.0) 100 (18.7) 210 (19.4) 143 (19.0)
A, anaemia; ARNi, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; COPD, chronic obstructive pulmonary disease;
CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved
ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; ID, iron deficiency; IQR, interquartile range; LVEF, left ventricular ejection fraction; MRA,
mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; RASi, renin–angiotensin system inhibitor.
aIncluded in the multiple imputation models and logistic/Cox regressions.
supplementary Table S2). Most patients received 1000 mg of FCM
(online supplementary Figure S4). In particular, of 963 HFrEF
patients with ID, 24% received FCM and 47% of them had anaemia,
while corresponding proportions were 12% and 71% in HFmrEF,
and 15% and 80% in HFpEF (Graphical Abstract, online supplemen-
tary Tables S2 and S10–S12). Detailed information on geographical
distribution of FCM use in Sweden is shown in online supplemen-











.. Baseline characteristics and independent predictors
of ferric carboxymaltose use
Patients receiving FCM vs. non receiving FCM were less likely
encountered in outpatient care and more likely to have anaemia,
diabetes, ischaemic heart disease, HFrEF, and more severe HF (i.e.
higher NYHA class, higher NT-proBNP levels and lower blood
pressure) (online supplementary Table S2). They were also more
likely to receive MRAs, diuretics and device therapies.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Outcome analysis according to iron deficiency/anaemia (ID/A) status. CI, confidence interval; HF, heart failure; HR, hazard ratio.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
8 P.M. Becher et al.
Table 3 Outcome analyses according to iron deficiency/anaemia status
Outcome ID−/A− ID−/A+ ID+/A− ID+/A+
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
All-cause death/first HF hospitalization
Event rates (*1000 pt-years) 160 (143–178) 312 (272–356) 198 (176–221) 405 (365–448)
Crude HR (95% CI), P-value Reference 1.90 (1.60–2.26), <0.001 1.23 (1.06–1.44), 0.008 2.46 (2.12–2.85), <0.001
Adjusted HR (95% CI), P-value Reference 1.23 (1.03–1.48), 0.024 1.12 (0.96–1.31), 0.160 1.48 (1.25–1.74), <0.001
All-cause death
Event rates (*1000 pt-years) 62 (53–74) 166 (140–197) 69 (57–82) 190 (166–217)
Crude HR (95% CI), P-value Reference 2.68 (2.12–3.38), <0.001 1.10 (0.87–1.40), 0.433 3.05 (2.47–3.76), <0.001
Adjusted HR (95% CI), P-value Reference 1.41 (1.10–1.82), 0.008 0.96 (0.75–1.22), 0.727 1.55 (1.23–1.95), <0.001
First HF hospitalization
Event rates (*1000 pt-years) 125 (110–141) 214 (181–251) 156 (137–176) 283 (250–319)
Crude HR (95% CI), P-value Reference 1.65 (1.35–2.02), <0.001 1.24 (1.05–1.48), 0.014 2.17 (1.83–2.58), <0.001
Adjusted HR (95% CI), P-value Reference 1.11 (0.89–1.37), 0.350 1.14 (0.95–1.36), 0.163 1.38 (1.14–1.67), 0.001
HF hospitalizations
Event rates (*1000 pt-years) 224 (205–244) 339 (300–381) 292 (268–317) 423 (386–461)
Crude IRR (95% CI), P-value Reference 1.72 (1.34–2.22), <0.001 1.30 (1.06–1.60), 0.012 2.12 (1.70–2.65), <0.001
Adjusted IRR (95% CI), P-value Reference 0.98 (0.76–1.25), 0.850 1.16 (0.95–1.42), 0.141 1.37 (1.10–1.72), 0.005
First all-cause hospitalization
Event rates (*1000 pt-years) 419 (388–452) 701 (629–778) 477 (439–517) 943 (867–1023)
Crude HR (95% CI), P-value Reference 1.60 (1.40–1.82), <0.001 1.13 (1.02–1.27), 0.026 2.10 (1.88–2.35), <0.001
Adjusted HR (95% CI), P-value Reference 1.11 (0.97–1.28), 0.128 1.04 (0.92–1.16), 0.551 1.39 (1.23–1.58), <0.001
All-cause hospitalizations
Event rates (*1000 pt-years) 677 (644–712) 1228 (1153–1306) 871 (829–915) 1438 (1370–1508)
Crude IRR (95% CI), P-value Reference 1.98 (1.71–2.29), <0.001 1.30 (1.15–1.46), <0.001 2.34 (2.06–2.66), <0.001
Adjusted IRR (95% CI), P-value Reference 1.30 (1.12–1.50), <0.001 1.17 (1.04–1.31), 0.008 1.43 (1.25–1.63), <0.001
First HF visit
Event rates (*1000 pt-years) 710 (664–759) 753 (674–839) 721 (669–777) 698 (635–766)
Crude HR (95% CI), P-value Reference 1.05 (0.92–1.19), 0.463 1.03 (0.93–1.14), 0.525 1.00 (0.89–1.12), 0.992
Adjusted HR (95% CI), P-value Reference 1.05 (0.92–1.20), 0.473 1.06 (0.96–1.17), 0.278 1.05 (0.92–1.19), 0.480
HF visits
Event rates (*1000 pt-years) 993 (952–1034) 1050 (982–1123) 1034 (989–1081) 1062 (1004–1122)
Crude IRR (95% CI), P-value Reference 1.09 (0.96–1.25), 0.183 1.06 (0.95–1.17), 0.298 1.10 (0.98–1.24), 0.098
Adjusted IRR (95% CI), P-value Reference 1.04 (0.91–1.18), 0.567 1.08 (0.98–1.19), 0.110 1.04 (0.93–1.17), 0.495
A, anaemia; CI, confidence interval; HF, heart failure; HR, hazard ratio; ID, iron deficiency; IRR, incident rate ratio; pt, patient.
Of all the variables which were tested in our multivariable model,
patient characteristics independently associated with FCM use
were more severe HF (i.e. higher NYHA class and MRA use), HFrEF
vs. HFmrEF vs. HFpEF, lower haemoglobin levels, diabetes, and
follow-up to specialty care (Figure 1). FCM use did not significantly
differ in 2017 vs. 2018 (P = 0.067) (Figure 1).
Discussion
This analysis from SwedeHF demonstrated six major findings: (i)
testing for diagnosing ID was performed only in approximately
a quarter of our HF population; (ii) key patient characteristics
associated with ID testing were anaemia, HFrEF, more severe
HF, and more specialized follow-up; (iii) ID was highly prevalent,
i.e. observed in half of the population; (iv) comorbid ID and
anaemia were associated with the highest risk of morbidity and

























.. hospitalizations; (v) only one out of five patients with an indication
received FCM treatment; and (vi) patients receiving FCM had
more severe HF and higher burden of comorbidities including
anaemia.
Iron deficiency testing and burden of iron
deficiency in real-world heart failure
Previous studies report the prevalence of ID in HF ranging between
35% and 43%.12,13 Consistently, routine evaluation of iron status in
HF is recommended by international guidelines.4
We observed that ID testing was performed in only about a
quarter of the population. Anaemia was among the strongest pre-
dictors of ID testing, with the likelihood of being tested increasing
with lower haemoglobin levels, which might suggest a diagnostic
work-up for anaemia rather than screening for ID in HF, which is
both prognostic and treatable regardless of anaemia.14
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Consistent with other studies, half of our HF population had
ID.15 We found that HF patients who were tested for ID had
more symptomatic HF, which might highlight physicians’ efforts
to identify non-cardiac causes of dyspnoea and, potentially, to
consider treatment of ID when diagnosed. Patients who were
tested for ID were more likely to receive HF treatments, which
might suggest that those receiving optimal care in terms of HF
treatments are also more likely tested for ID as part of the HF
management. Consistently, ID testing was associated with referral
to HF nurse-led clinic, which might be explained by an enhanced
multidisciplinary care in these patients and by HF nurse teams
administering IV iron treatment as part of the optimization of HF
therapy.16 ID testing was more frequent in an outpatient setting,
which is counterintuitive since ID might be more easily treated
during a hospitalization for HF when IV iron treatment might
further help in the amelioration of HF symptoms. The likelihood
of being tested for ID was higher in HFrEF although recommended
by guidelines in HF regardless of EF. This might indicate that physi-
cians might be more likely to search for ID in a setting where there
is good evidence and clear recommendation for treatment, i.e.
FCM use in HFrEF.4 However, undertesting is not only observed
for ID in HF, with natriuretic peptide assessment still limitedly
implemented although there is clear evidence for its diagnostic and
prognostic role.17
In our study, we explored the different profiles of patients with
vs. without ID, also stratifying by anaemia status. Importantly, a
significant proportion of our population had ID without anaemia
(29%), which is consistent with findings from previous stud-
ies (32%).12 Patients with ID+/anaemia− had a profile overall
resembling more ID−/anaemia− than ID+/anaemia+ in terms of
comorbidity burden and HF severity. In accordance with previous
studies, we found that patients with ID+/anaemia− were more
likely female, had higher NT-proBNP levels, higher NYHA class,
and slightly impaired renal function compared with patients with
ID−/anaemia−,12,18 whereas highest NT-proBNP levels and NYHA
class were observed in patients with anaemia regardless of ID,
who also reported the highest comorbidity burden.1,13,19 Con-
sistently with previous studies, we observed the most impaired
renal function in patients with anaemia with and without ID,20–22
with anaemia having been shown in other analyses as an additional
marker of severity rather than a causal factor of chronic kidney
disease.23
Consistent with these differences in patient profiles and in
agreement with previous reports, we could show that patients with
concomitant anaemia and ID were at highest risk of mortality.1,24
However, those analyses highlighted higher risk of all-cause death in
patients with ID without anaemia and no prognostic role of anaemia
in absence of ID, whereas we observed higher mortality with
anaemia without ID and no significantly increased risk of all-cause
death in those with ID without anaemia.1,24 These discrepancies
might be at least partially explained by selection bias and residual
confounding, with patients with anaemia and more advanced HF
being more likely to be tested and thus included in the current
study compared with those with severe HF but without anaemia.
Even if there was a bias in our analysis, we could provide an overall



















































































.. in ID testing in real-world HF. We also showed that the risk of
recurrent all-cause hospitalizations was higher in patients with ID
regardless of concomitant anaemia, with similar HRs for recurrent
HF hospitalizations although in absence of statistically significance
likely due to sample size issues. The finding of increased risk of
hospitalizations with ID appears consistent with RCTs showing
reductions in cardiovascular/HF hospitalizations without an effect
on mortality alone with FCM.8,9
Finally, we observed that transferrin saturation <20% vs. ≥20%
was associated with higher risk of all investigated outcomes after
adjustments for ferritin levels and other patient characteristics,
whereas ferritin <100 μg/L vs. ≥100 μg/L was only associated with
higher risk of recurrent all-cause hospitalizations and recurrent
HF hospitalizations after adjustment for transferrin saturation and
other potential confounders. These findings are consistent with
previous studies suggesting a worse prognostic role for transferrin
saturation <20% regardless of ferritin levels, anaemia, and other
comorbidities.24,25 Consistently, it has been previously shown that
an impaired iron transport (transferrin saturation <20%) but not
impaired iron storage (ferritin <100 μg/L) is independently asso-
ciated with increased sympathetic activation, i.e. elevated nore-
pinephrine levels, in patients with chronic HF.26
Use of ferric carboxymaltose
in real-world care
Pooled data from several RCTs have highlighted a role for IV iron
in reducing the combined risk of all-cause death or cardiovascular
hospitalization, alleviating HF symptoms, and improving exercise
capacity and quality of life.8 Accordingly,4,6,8 the European and US
guidelines recommend that IV iron treatment should be offered
to symptomatic patients with HFrEF and ID, but the class of rec-
ommendation varies between IIa and IIb.4,27 Additionally, beyond
impacting outcomes, quality of life and improving symptoms, data
from the AFFIRM-AHF trial have shown that treatment with FCM
is also highly cost-effective in patients with ID stabilized after a
hospitalization for acute HF,28 which was mainly explained by the
reduction in HF hospitalizations.
There are currently scarce data on the use of IV iron treatment in
real-world HF, with few studies suggesting limited implementation,
i.e. ranging between 3% and 24%.15 We observed that 19% of
our HF population with ID received FCM treatment, more than
half of them with concomitant anaemia, and, as expected, use was
highest in HFrEF. These data highlight that despite current guideline
recommendation, FCM is still underutilized in HF patients in clinical
practice. This is also in line with the observed underutilization of
several guideline-recommended medications, device therapies and
multidisciplinary strategies in HF.16,29–31 In our analysis, key patient
characteristics independently associated with FCM use were more
severe HF and a higher burden of comorbidities including anaemia,
which might highlight the attempt to reduce symptoms by treating
ID. While ID testing use was more common in an outpatient
setting, FCM was more likely used in inpatients, which might
indicate that although patients are diagnosed with ID, treatment
might not occur after ID testing but might be delayed in some
cases until an urgent hospitalization due to clinical inertia or
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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prioritization or logistical issues. Anaemia was not only a major
determinant for ID screening, but was also associated with FCM
administration. This finding underlines the commonly held belief
that treating ID is only needed in the presence or on the basis of
the degree of anaemia.
Limitations
Our study has several limitations that should be acknowledged.
First, we defined missing values for ID biomarkers as lack of
testing. However, some patients might have been tested for
ferritin/transferrin saturation levels, but the values could not
have been entered in the registry. Second, our data suggest that
testing was performed for suspect of anaemia rather than of ID,
which might have led to overestimate the prevalence of anaemia
and underestimate that of ID. Third, repeated assessment of
ferritin/transferrin saturation levels and of FCM use was not
available, which prevented to capture later use of FCM during
follow-up and to investigate the longitudinal relationship between
ferritin/transferrin saturation levels, ID status and treatment with
FCM. Forth, in SwedeHF there is no information regarding the
indications underlying the prescription of specific medications.
Therefore, we could only assume that patients receiving FCM
but with normal ferritin/transferrin saturation levels had ID which
had been successfully treated with FCM. Finally, SwedeHF is a
nationwide continuous registry, but it does not have complete
coverage and enrols primarily patients in secondary care. There-
fore, selection bias may still represent a limitation, with better
treated patients enrolled in our registry, which could have led to
overestimate FCM use.32
Conclusion
In this nationwide HF registry, ID testing was performed in only
about a quarter of the population. ID was highly prevalent, i.e. half
of the study cohort, but only one in five patients with ID received
FCM treatment. A major determinant for limited testing and
treatment of ID was the lack of concomitant anaemia. Consistently,
ID testing rates were higher in patients with vs. without anaemia.
This highlights the misconception that ID is a treatment target
only in the presence of anaemia. Our data indicate low adherence
to current guidelines in terms of screening for and treatment
of ID in HF patients. Appropriate diagnostic and interventional
strategies are needed to improve ID management and overall
HF care.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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